Behind many research careers is a personal story. In a recent essay in Science, a cancer survivor and researcher shares how being open about their diagnosis reshaped their Ph.D. journey and their work in science. Lived experience in research The essay offers a thoughtful look at how lived experience can guide the questions scientists ask and the care they bring...

The Appendix Cancer PMP (ACPMP) Research Foundation, in partnership with the National Organization for Rare Disorders (NORD), has launched the first-ever ACPMP Research Foundation Appendix Cancer/Pseudomyxoma Peritonei Patient Registry (ACPMP Patient Registry). The Registry provides a secure platform for patients and caregivers worldwide to share information about appendix cancer and pseudomyxoma peritonei (PMP). "The ACPMP Patient Registry will provide a...

New research shows just how powerful personalized cancer treatment can be. A landmark clinical trial led by researchers at the University of California San Diego found that tailoring treatment to the unique DNA of each patient's tumor significantly improved outcomes – without increasing severe side effects. The findings were published in the Journal of Clinical Oncology. How the trial worked...

Article written by Nare Hovhannisyan, MD on OncoDaily.com For decades, appendiceal cancer was the orphan cousin of colorectal cancer tucked away under a brief note in major guidelines, its complexities reduced to “follow colorectal protocols”. Now, for the first time, the National Comprehensive Cancer Network (NCCN) has given this rare malignancy its own voice. The newly released NCCN Guidelines for Appendiceal Cancer mark a milestone,...

SPRINGFIELD, PA, UNITED STATES, October 8, 2025 /EINPresswire.com/ -- The Appendix Cancer PMP Research Foundation (ACPMP), a nonprofit dedicated to funding research, raising awareness, and providing patient support for appendix cancer and pseudomyxoma peritonei (PMP), today announced a landmark investment in research and education aimed at accelerating progress for patients facing these rare cancers. Thanks to the generosity of ACPMP donors, peer-to-peer...

We are thrilled to share an important milestone for patients with pseudomyxoma peritonei (PMP). Dr. Kjersti Flatmark and her team at Oslo University Hospital have received approval from Norwegian regulatory authorities to begin a clinical trial of Pseudovax, a vaccine being developed as a potential new treatment for PMP. About the Pseudovax PMP vaccine trial Many PMP tumors carry a...

Please join us in celebrating ACPMP Medical Advisory Board member Dr. John Paul Shen, a physician-scientist at MD Anderson Cancer Center, for being recognized by Conquer Cancer, the ASCO Foundation, for his work to improve outcomes for patients with appendix cancer! His research focuses on developing chemotherapy options designed specifically for appendix cancer, repurposing existing drugs, and addressing the unique...

We are proud to share new research led by our Scientific Advisory Board Chair, Dr. Andreana Holowatyj, and published in the Annals of Internal Medicine, finding that appendix cancer rates have quadrupled among Millennials. This landmark study, funded in part by The Appendix Cancer Research Foundation and the National Institutes of Health, was featured in The New York Times, TIME...

Dr. Muhammad Talha Waheed, a postdoctoral research fellow at City of Hope, was recently interviewed by Cancer Network about study findings he first presented in a poster at the 2025 Society of Surgical Oncology (SSO) Annual Meeting. The research looks at the timing of surgery for appendix cancer and suggests a staged colectomy may be preferable in some cases. What...

Appendix cancer has often been treated like colorectal cancer (CRC). A recent article in ASCO Daily News by Dr. John Paul Shen, a member of ACPMP's Medical Advisory Board, and Dr. Michael B. Foote, explains why that approach deserves a closer look – and what it means for appendix cancer chemotherapy and future treatment. Key differences between appendix and colorectal...